These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 34759826)

  • 1. Pharmacokinetic Engineering of OX40-Blocking Anticalin Proteins Using Monomeric Plasma Half-Life Extension Domains.
    Siegemund M; Oak P; Hansbauer EM; Allersdorfer A; Utschick K; Winter A; Grasmüller C; Galler G; Mayer JP; Weiche B; Prassler J; Kontermann RE; Rothe C
    Front Pharmacol; 2021; 12():759337. PubMed ID: 34759826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endogenous IgG-based affinity-controlled release of TRAIL exerts superior antitumor effects.
    Yang H; Feng Y; Cai H; Jia D; Li H; Tao Z; Zhong Y; Li Z; Shi Q; Wan L; Li L; Lu X
    Theranostics; 2018; 8(9):2459-2476. PubMed ID: 29721092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and biological evaluation of novel long-acting adalimumab Fab conjugated with the albumin binding domain.
    Zhang Q; Qian M; Wu Y; Wang Y; Shangguan W; Lu J; Zhao W; Feng J
    Eur J Pharmacol; 2021 Aug; 904():174152. PubMed ID: 33964292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extended plasma half-life of albumin-binding domain fused human IgA upon pH-dependent albumin engagement of human FcRn
    Mester S; Evers M; Meyer S; Nilsen J; Greiff V; Sandlie I; Leusen J; Andersen JT
    MAbs; 2021; 13(1):1893888. PubMed ID: 33691596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of affinity and valency of an albumin-binding domain (ABD) on the half-life of a single-chain diabody-ABD fusion protein.
    Hopp J; Hornig N; Zettlitz KA; Schwarz A; Fuss N; Müller D; Kontermann RE
    Protein Eng Des Sel; 2010 Nov; 23(11):827-34. PubMed ID: 20817756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cellular recycling-driven in vivo half-life extension using recombinant albumin fusions tuned for neonatal Fc receptor (FcRn) engagement.
    Larsen MT; Rawsthorne H; Schelde KK; Dagnæs-Hansen F; Cameron J; Howard KA
    J Control Release; 2018 Oct; 287():132-141. PubMed ID: 30016735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Fab-Selective Immunoglobulin-Binding Domain from Streptococcal Protein G with Improved Half-Life Extension Properties.
    Unverdorben F; Hutt M; Seifert O; Kontermann RE
    PLoS One; 2015; 10(10):e0139838. PubMed ID: 26430884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fusion with an albumin-binding domain improves pharmacokinetics of an αvβ3-integrin binding fibronectin scaffold protein.
    Gapizov SS; Petrovskaya LE; Shingarova LN; Kryukova EA; Boldyreva EF; Lukashev EP; Yakimov SA; Svirshchevskaya EV; Dolgikh DA; Kirpichnikov MP
    Biotechnol Appl Biochem; 2019 Jul; 66(4):617-625. PubMed ID: 31140614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy.
    Fromm G; de Silva S; Johannes K; Patel A; Hornblower JC; Schreiber TH
    J Immunother Cancer; 2018 Dec; 6(1):149. PubMed ID: 30563566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Half-life extension of a single-chain diabody by fusion to domain B of staphylococcal protein A.
    Unverdorben F; Färber-Schwarz A; Richter F; Hutt M; Kontermann RE
    Protein Eng Des Sel; 2012 Feb; 25(2):81-8. PubMed ID: 22238430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fusion to an albumin-binding domain with a high affinity for albumin extends the circulatory half-life and enhances the in vivo antitumor effects of human TRAIL.
    Li R; Yang H; Jia D; Nie Q; Cai H; Fan Q; Wan L; Li L; Lu X
    J Control Release; 2016 Apr; 228():96-106. PubMed ID: 26951928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extending Half Life of H-Ferritin Nanoparticle by Fusing Albumin Binding Domain for Doxorubicin Encapsulation.
    Wang C; Zhang C; Li Z; Yin S; Wang Q; Guo F; Zhang Y; Yu R; Liu Y; Su Z
    Biomacromolecules; 2018 Mar; 19(3):773-781. PubMed ID: 29328653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small Bispecific Affinity Proteins for Simultaneous Target Binding and Albumin-Associated Half-Life Extension.
    von Witting E; Lindbo S; Lundqvist M; Möller M; Wisniewski A; Kanje S; Rockberg J; Tegel H; Åstrand M; Uhlén M; Hober S
    Mol Pharm; 2021 Jan; 18(1):328-337. PubMed ID: 33259222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extending the half-life of a fab fragment through generation of a humanized anti-human serum albumin Fv domain: An investigation into the correlation between affinity and serum half-life.
    Adams R; Griffin L; Compson JE; Jairaj M; Baker T; Ceska T; West S; Zaccheo O; Davé E; Lawson AD; Humphreys DP; Heywood S
    MAbs; 2016 Oct; 8(7):1336-1346. PubMed ID: 27315033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Albumin-binding domain from Streptococcus zooepidemicus protein Zag as a novel strategy to improve the half-life of therapeutic proteins.
    Cantante C; Lourenço S; Morais M; Leandro J; Gano L; Silva N; Leandro P; Serrano M; Henriques AO; Andre A; Cunha-Santos C; Fontes C; Correia JDG; Aires-da-Silva F; Goncalves J
    J Biotechnol; 2017 Jul; 253():23-33. PubMed ID: 28549690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Programmable half-life and anti-tumour effects of bispecific T-cell engager-albumin fusions with tuned FcRn affinity.
    Mandrup OA; Ong SC; Lykkemark S; Dinesen A; Rudnik-Jansen I; Dagnæs-Hansen NF; Andersen JT; Alvarez-Vallina L; Howard KA
    Commun Biol; 2021 Mar; 4(1):310. PubMed ID: 33686177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biodistribution of a bispecific single-chain diabody and its half-life extended derivatives.
    Stork R; Campigna E; Robert B; Müller D; Kontermann RE
    J Biol Chem; 2009 Sep; 284(38):25612-9. PubMed ID: 19628871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel tri-functional antibody fusion protein with improved pharmacokinetic properties generated by fusing a bispecific single-chain diabody with an albumin-binding domain from streptococcal protein G.
    Stork R; Müller D; Kontermann RE
    Protein Eng Des Sel; 2007 Nov; 20(11):569-76. PubMed ID: 17982179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Affinity and kinetics of the interaction between soluble trimeric OX40 ligand, a member of the tumor necrosis factor superfamily, and its receptor OX40 on activated T cells.
    Al-Shamkhani A; Mallett S; Brown MH; James W; Barclay AN
    J Biol Chem; 1997 Feb; 272(8):5275-82. PubMed ID: 9030600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploring a novel long-acting glucagon-like peptide-1 receptor agonist built on the albumin-binding domain and XTEN scaffolds.
    Zhou Y; Li J; Gao G; Li Y; Zhang C
    Heliyon; 2024 Jan; 10(2):e24340. PubMed ID: 38293540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.